Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 06, 2023, titled "Sentynl Therapeutics Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease from Cyprium Therapeutics".
Zydus Lifesciences Limited Press Release Dec 06 2023
Filed with NSE · · 3 pages · English
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Dec 01 2023
- Press Release Nov 10 2023
- Press Release Nov 07 2023
- Press Release Nov 06 2023
- Press Release Nov 03 2023
Later from Zydus Lifesciences
- Zydus Lifesciences Limited Press Release Dec 11 2023
- Press Release Dec 14 2023
- Press Release Dec 15 2023
- Press Release Dec 16 2023
- Press Release Dec 22 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences